Prevenar 13 catch-up dose funding delay criticised

FEDERAL Cabinet’s delay in funding the catch-up program for 13-valent pneumococcal vaccine is inviting “a political response” from patients and its manufacturer which will rightly spark debate about how health dollars are spent, the AMA says.

While pneumococcal disease had a low incidence, when it occurred it was serious, and the likelihood was a child would “get sick from pneumococcal, and it’s going to be on the front page of the newspaper”, AMA vice-president GP Dr Steve Hambleton